O Péter

3.8k total citations
65 papers, 2.7k citations indexed

About

O Péter is a scholar working on Parasitology, Infectious Diseases and Ecology, Evolution, Behavior and Systematics. According to data from OpenAlex, O Péter has authored 65 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Parasitology, 22 papers in Infectious Diseases and 16 papers in Ecology, Evolution, Behavior and Systematics. Recurrent topics in O Péter's work include Vector-borne infectious diseases (48 papers), Viral Infections and Vectors (20 papers) and Vector-Borne Animal Diseases (16 papers). O Péter is often cited by papers focused on Vector-borne infectious diseases (48 papers), Viral Infections and Vectors (20 papers) and Vector-Borne Animal Diseases (16 papers). O Péter collaborates with scholars based in Switzerland, France and United States. O Péter's co-authors include Erich Brunner, Konrad Basler, Liang Schweizer, Willy Burgdorfer, Georges Dupuis, G. Baranton, M G Peacock, Anne Le Flèche‐Matéos, Thomas Kramps and Denise Nellen and has published in prestigious journals such as Nature, Cell and PLoS ONE.

In The Last Decade

O Péter

61 papers receiving 2.6k citations

Peers

Countries citing papers authored by O Péter

Since Specialization

Citations

This map shows the geographic impact of O Péter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by O Péter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites O Péter more than expected).

Fields of papers citing papers by O Péter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by O Péter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by O Péter. The network helps show where O Péter may publish in the future.

Co-authorship network of co-authors of O Péter

This figure shows the co-authorship network connecting the top 25 collaborators of O Péter. A scholar is included among the top collaborators of O Péter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with O Péter. O Péter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An out-of-hours cell culture autopilot proof of concept based on a modular architecture using the SiLA2 open standard 2025 ·SLAS TECHNOLOGY ·Patrick Courtney, (unknown), (unknown), (unknown), (unknown), (unknown), O Péter	0
2	Novel high–throughput myofibroblast assays identify agonists with therapeutic potential in pulmonary fibrosis that act via EP2 and EP4 receptors 2018 ·PLoS ONE ·Patrick Sieber, (unknown), (unknown), (unknown), Manuel Stritt, Richard W.D. Welford, John Gatfield, O Péter, Oliver Nayler, Urs Lüthi	23
3	Q fever outbreak in the terraced vineyards of Lavaux, Switzerland 2014 ·New Microbes and New Infections ·Chiara Bellini, Ioannis Magouras, Caroline Chapuis‐Taillard, Olivier Clerc, Éric Masserey, (unknown), O Péter, (unknown), (unknown), Gilbert Greub	32
4	Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffold 2012 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), (unknown), Dorte Renneberg, Markus A. Riederer, O Péter, Xavier Leroy, Carmela Gnerre, Heinz Fretz	7
5	Bilateral clavicle fracture external fixation 2010 ·Orthopaedics & Traumatology Surgery & Research ·Nicolas Bonnevialle, (unknown), Pierre Mansat, O Péter, (unknown), P. Bonnevialle	14
6	Terrible triad injury of the elbow: How to improve outcomes? 2010 ·Orthopaedics & Traumatology Surgery & Research ·(unknown), Nicolas Bonnevialle, O Péter, Pierre Mansat, P. Bonnevialle	60
7	Terrible triade du coude : description et prise en charge 2010 ·Revue de Chirurgie Orthopédique et Traumatologique ·(unknown), Nicolas Bonnevialle, O Péter, Pierre Mansat, P. Bonnevialle	8
8	Attaques cérébrovasculaires ischémiques multiples dues à une méningovasculite à Borrelia garinii 2010 ·Revue Neurologique ·(unknown), Renaud Du Pasquier, (unknown), O Péter, Patrik Michel	7
9	Érythème borrélien de la face 2008 ·Annales de Dermatologie et de Vénéréologie ·(unknown), O Péter, (unknown), Emmanuel Laffitte	1
10	Borréliose de Lyme - 3ème partie : Prévention, grossesse, états d'immunodéficience, syndrome post-borréliose de Lyme 2006 ·Archive ouverte UNIGE (University of Geneva) ·(unknown), Christoph Aebi, P Francioli, O Péter, Stefano Bassetti, Alain Gervaix, (unknown), (unknown)	0
11	Abklärung und Therapie der Lyme-Borreliose bei Erwachsenen und Kindern: Empfehlungen der Schweizerischen Gesellschaft für Infektiologie. Teil 1: Epidemiologie und Diagnostik 2005 ·Schweizerische Ärztezeitung ·(unknown), Christoph Aebi, P Francioli, O Péter, (unknown), Alain Gervaix, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2
12	Abklärung und Therapie der Lyme-Borreliose bei Erwachsenen und Kindern: Empfehlungen der Schweizerischen Gesellschaft für Infektiologie. Teil 3: Prävention, Schwangerschaft, Immundefizienz, Post-Lyme-Syndrom 2005 ·Schweizerische Ärztezeitung ·(unknown), Christoph Aebi, P Francioli, O Péter, (unknown), Alain Gervaix, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	3
13	Abklärung und Therapie der Lyme-Borreliose bei Erwachsenen und Kindern: Empfehlungen der Schweizerischen Gesellschaft für Infektiologie. Teil 2: Klinik und Therapie 2005 ·Schweizerische Ärztezeitung ·(unknown), Christoph Aebi, P Francioli, O Péter, (unknown), Alain Gervaix, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	7
14	Wnt/Wingless Signaling Requires BCL9/Legless-Mediated Recruitment of Pygopus to the Nuclear β-Catenin-TCF Complex 2002 ·Cell ·Thomas Kramps, O Péter, Erich Brunner, Denise Nellen, Barbara A. Froesch, Sandipan Chatterjee, Maximilien Murone, (unknown), Konrad Basler	463
15	Amino-terminal control of transgenic protein expression levels in Toxoplasma gondii 2002 ·Molecular and Biochemical Parasitology ·Mariana Matrajt, Manami Nishi, Martin Fraunholz, O Péter, David S. Roos	24
16	Routine diagnosis of Borrelia burgdorferi (sensu lato) infections using a real-time PCR assay 2001 ·Clinical Microbiology and Infection ·(unknown), O Péter, P. Cassinotti	94
17	Genetic and Phenotypic Analysis of Borrelia valaisiana sp. nov. (Borrelia Genomic Groups VS116 and M19) 1997 ·International Journal of Systematic Bacteriology ·(unknown), Alje P. van Dam, Anne Le Flèche‐Matéos, D. Postic, O Péter, G. Baranton, R. de Boer, Lodewijk Spanjaard, J. Dankert	162
18	Occurrence of different genospecies ofBorrelia burgdorferi sensu lato in ixodid ticks of Valais, Switzerland 1995 ·European Journal of Epidemiology ·O Péter, (unknown), (unknown)	57
19	Serological diagnosis of Q fever endocarditis 1986 ·European Heart Journal ·Georges Dupuis, O Péter, (unknown), J. Nicolet, M G Peacock, Willy Burgdorfer	21
20	Ixodes ricinus: vector of a hitherto undescribed spotted fever group agent in Switzerland. 1979 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Willy Burgdorfer, André Aeschlimann, O Péter, (unknown), (unknown)	95

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact